Contraceptive Technology Update
RSSArticles
-
Antifungal drug tied to miscarriage risk
In a retrospective analysis of 1.4 million pregnancies in Denmark, use of the oral antifungal medication fluconazole during pregnancy was tied to a significantly increased risk of spontaneous abortion associated with fluconazole exposure (HR, 1.48; 95%CI, 1.23-1.77), compared with risk among unexposed women and women who used a topical antifungal during pregnancy. Until more data on the association are available, cautious prescribing of fluconazole in pregnancy might be advisable. Although the risk of stillbirth wasn’t significantly increased, this outcome should be investigated further.1
-
Could premenstrual syndrome be a flag for future risk of hypertension?
Results of a new study indicate that women with moderate-to-severe PMS had a 40% higher risk of developing high blood pressure during the following 20 years compared to women experiencing few menstrual symptoms.1
-
Push is on to increase postpartum use of LARC
Your next patient is a young mother of two, and her youngest child is less than a year old. While she was using combined oral contraceptives to prevent pregnancy, her busy schedule compromised compliance. The lab results are in: The pregnancy test is positive.
-
HPV vaccine update: Get up to speed
Healthcare professionals need to be familiar with all of the indications for the human papillomavirus vaccine, make strong recommendations for receiving vaccine at ages 11 or 12, and be aware of systems that can improve practice vaccination rates.
-
Chlamydia, gonorrhea, and syphilis cases are up for first time since 2006
Reported cases of chlamydia, gonorrhea, and syphilis have increased for the first time since 2006, according to just-published data by the Centers for Disease Control and Prevention.
-
Where do pills fit in the family planning picture?
In national statistics, the pill continues to lead the pack, with 25.9% of contracepting women (9.7 million women) reporting its use. Female sterilization was listed by 25.1% (9.4 million women), followed by the male condom (15.3%, 5.8 million women) and long-acting reversible contraception (11.6%, 4.4 million women).
-
Should oral contraceptives move over the counter? Readers speak out
Most participants in the Contraceptive Technology Update Contraception Survey say they support moving oral contraceptives over the counter. Almost 50% say they would support OTC availability of progestin-only pills, while 32% say they would support similar availability of combined hormonal pills.
-
Focus on the contraceptive implant — Insert it in your family planning practice
About 30% of participants in the 2015 Contraceptive Technology Update Contraception Survey reported 25 or more implant insertions in the past year, with 14% saying they inserted 11 to 24 devices.
-
Survey profile
The 2015 Contraceptive Technology Update Contraception Survey monitors contraceptive trends and family planning issues among readers. Results were tallied and analyzed by AHC Media in Atlanta, which publishes CTU and dozens of other healthcare newsletters and sourcebooks and presents webinars and conferences.
-
Survey results show use of LARC continues to rise
About 46% of participants in the 2015 Contraceptive Technology Update Contraception Survey say they have seen “dramatically more” women choosing long-acting reversible contraceptive methods such as the intrauterine device and contraceptive implant in the last year.